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A B S T R A C T
Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) have been investigated in a single
neurodegenerative disease manifesting as either amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD)
alone, but have not been examined in combined disorders such as ALS with FTD (ALS-FTD). To our knowledge, this
study is the first attempt to demonstrate relationship between MRI abnormalities and MR spectroscopic metabolite chan-
ges of the motor cortex, frontal white matter and corticospinal tract in a patient with the diagnosis of ALS with probable
upper motor neuron signs (ALS-PUMNS) and FTD. Patient presented underwent MRI of the brain and MRS. The ratio
of N-acetylaspartate (NAA) to creatine (Cr), choline to Cr, myo-inositol (mI) to Cr and glutamate-glutamine (Glx) to Cr
were derived from peak area measurement. Spectra from the right motor cortex, frontal white matter and corticospinal
tract were obtained. MR images were evaluated for sulcus centralis enlargement, corticospinal tract hyperintensity and
frontal lobes atrophy. Spectra showed reduced NAA/Cr and Glx/Cr ratio, yet the ratio of Cho/Cr exhibited significant ele-
vation. MR images revealed sulcus centralis enlargement, high signal intensity of corticospinal tract and atrophy of both
frontal lobes. Proton spectroscopic metabolic changes in a current patient fully correlate with previously reported MRS
metabolic changes in ALS alone. Surprisingly, normal mI (glial marker) values have been found in almost all measured
voxels of interest except in the frontal white matter. These findings differ from the previous findings in ALS or FTD
alone. In conclusion, these findings support the concept that ALS, FTD and ALS-FTD may represent different manifes-
tations of a single pathological continuum.
Key words: magnetic resonance imaging, magnetic resonance spectroscopy, amyotrophic lateral sclerosis, fronto-
temporal dementia.
Introduction
Recent literature provided neuroradiologic1,2 neuro-
cognitive3,4 neuropathologic5 and genetic6 evidence of
possible association between amyotrophic lateral sclero-
sis (ALS) and frontotemporal dementia (FTD). These re-
ports suggest that ALS and FTD represent two points of
a single pathological continuum and affect the same
neuroanatomic substrate7–9. Currently, the antemortem
diagnosis of ALS is based on a spectrum of clinical,
electrophysiological, and sometimes, muscle biopsy fin-
dings10. The diagnosis of FTD is established by using in-
ternational clinical criteria11,12 and supported by electro-
physiological findings and brain imaging. There is no
definitive diagnostic test for ALS-FTD condition, and the
interest in the diagnostic value of the magnetic reso-
nance imaging (MRI) and magnetic resonance spectro-
scopy (MRS) of the brain in these patients has aroused.
Brain imaging and proton spectroscopy have been inves-
tigated in a single neurodegenerative disease manifest-
ing as either amyotrophic lateral sclerosis2 (ALS) or
frontotemporal dementia (FTD) alone13,14, but no evi-
dence has been reported to demonstrate MRS metabolic
changes of the brain in relation with MR signal changes
in patient with both ALS and FTD.
In vivo proton spectroscopy studies of the precentral
gyrus (motor cortex) regions in ALS patients have shown:
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a decrease in the peak area ratio of N-acetyl aspartate to
total creatine (NAA/Cr)15, in the ratio of NAA to Cr plus
choline (Cho)16, in the ratio of glutamate and glutamine
(Glx) to Cr (Glx/Cr), or elevation in the peak area ratio of
Cho to Cr ratio and in the ratio of myo-inositol to Cr
(mI/Cr) in precentral gyrus17, motor cortex and cuneus
gyrus2. So far, no attempt has been made to relate imag-
ing findings and in vivo MR spectroscopic metabolic
changes of precentral gyrus, frontal white matter and
corticospinal tracts in a patient with both ALS-FTD con-
dition.
Clinical evaluation
A 54-year-old woman with a negative family history
was initially seen for evaluation of upper limb weakness
and dysarthria that has developed for a past two years.
She completed in teacher degree, married and worked
successfully until her early-50s, when she retired. At age
52, she exhibited behaviour changes, apathy, agitation,
memory disturbances, disorientation associated with
changes in social and personal conduct that has becom-
ing progressively worse. She noticed slurred speech and
difficulty with swallowing. Her Mini-Mental State Exam-
ination score was 25 of 30. On neurological examination
she exhibited euphoria and disinhibition. Cranial nerves
examination has shown brisk jaw jerks, slurred speech
and tongue fasciculation. Arms were 3/5 and legs 4/5 in
strength, more pronounced for the left side. She had tri-
ceps muscles fasciculation. Reflexes were normal thro-
ughout. Except diminished fine motor coordination, any
of other upper motor neuron (UMN) signs have been ob-
served including Hoffmann sign, Babinski sign, clonus or
snout reflex. The diagnosis of ALS with probable upper
motor neuron signs (ALS-PUMNS) was highly likely. In
addition, no clinical signs of sensory loss, sphincter prob-
lems, visual disturbances or autonomic dysfunction have
been detected. Electromyography revealed acute and chro-
nic denervation. Disease severity was 12 according to the
Jablecki et all score18. We found significant deficits on
the Recognition Memory Test, Wisconsin Card Sorting
Test, Consonant Trigrams Test and Block Design Test,
Frontal behavioural scale19, BEHAVE-AD20, Neuropsy-
chiatric Inventory21, Frontal Behavioral Inventory22. In
the absence of neuropathologic findings, neurologist has
established the diagnosis of ALS and FTD primarily
based on a spectrum of clinical features10,11 and sup-
ported by additional investigations including, neuropsy-
chology, electrophysiology, MR imaging and MR spectro-
scopy.
Brain Imaging Studies
All MR investigations were conducted with a 2.0-T
MR imager (GE Medical Systems) at the Croatian Insti-
tute for Brain Research, School of Medicine, University
of Zagreb, Diagnostic Center »Neuron». A brain MRI
protocol included the following: a) T1-weighted spin-
-echo (SE) sagittal imaging (650/12/1, field of view, 23 cm;
imaging matrix, 256 × 256, section thickness, 5 mm); b)
T2-weighted fast spin-echo (FSE) coronal imaging (5600/
90; field of view, 23 × 23 cm; imaging matrix, 250 × 296;
section thickness, 5 mm); c) T2-weighted FSE axial im-
aging (8500/2200/126; field of view, 23 × 26 cm; imaging
matrix, 252 × 296; section thickness, 5 mm); and d)
EPI–SE diffusion weighted imaging (DWI) axial imaging
(3000/108; field of view, 37.3 × 23.1 cm imaging matrix,
128 × 128; section thickness, 5 mm). The brain MRI eval-
uation was followed by the brain MRS study. MRI and
MRSwere evaluated blind to the conditions of the patient.
MR images were interpreted by one neuroradiologist
(G.P.) for the following signs:
a) enlargement of the central sulcus on sagittal T1-SE,
b) atrophy of frontal and temporal lobes on coronal T2-
-FSE, c) increased signal intensity within the cortico-
spinal tracts in the posterior limb of the internal cap-
sule at the level of the anterior commisure and hypo-
intensity of precentral gyrus (motor cortex) on axial
FSE and DWI.
MR images features in the sagittal T1-SE (Figure 1)
sequences show atrophy of the frontal lobes and enlarge-
ment of the central sulcus; in the coronal T2-FSE (Fig-
ure 2) demonstrate dilated subarachnoid space over fron-
tal lobes signifying atrophy; in the axial T2-FSE (Figure
3) at the level of anterior commissure, increased signal
intensity (arrows) was depicted within the right and left
corticospinal tracts (within the posterior limbs of both
internal capsules); in the axial EPI-SE DWI (Figure 4)
show increased signal (lower diffusivity); in the corti-
cospinal tracts at the level of anterior commisure in the
axial EPI-SE-DWI (Figure 5) show a curvilinear hypo-
intensity (arrows) in the region of the motor cortex of the
precentral gyri.
MRI evaluation that consisted of T2-FSE axial imag-
ing have been followed by the single-voxel proton MRS.
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Fig.1. Sagittal T1- weighted spin-echo (SE) image (650/12 with
one signal acquired) in a 54-year-old woman with ALS – FTD
shows enlargement of the central sulcus (arrow) and atrophy of
the frontal lobe. ALS – amyotrophic lateral sclerosis, FTD – fron-
totemporal dementia.
The single-voxel proton MR spectroscopic studies were
performed with a point-resolved spectroscopic sequence,
supplied by the manufacturer (1500754). Preimaging re-
quired about 4 minutes, and imaging required 8 minutes
to obtain each MRS spectrum. Spectra were obtained
and analyzed by one observer (G.P.). We used metabolite
ratios found in published literature23,24 and compared
with our results of metabolite ratios. This approach
seems to be very useful because metabolite ratios are the
same measured in any group of controls with any scan-
ner and anywhere, and differ in various diseases. The
metabolite ratios were obtained because of the time con-
suming and technical limitations of the clinical applica-
tion of quantitative proton spectroscopy25.
Peak area ratios of NAA/Cr, NAA/Cho, Cho/Cr, Glx/Cr
and mI/Cr in the right precentral gyrus (motor cortex),
right frontal white matter and right corticospinal tract
were calculated. Because of limited availability of the MR
imager, other voxels of interest (VOI) were omitted, as
was the MR imaging study of the cervical spine.
Axial T2-FSE images (8500/2200/126) were obtained,
followed by placement of a single 8-cm3 voxel (2 × 2 × 2
cm) over right motor cortex, right frontal white matter
and corticospinal tracts at the level of anterior commi-
sure and cerebral peduncle. MR spectroscopy demon-
strated peaks of NAA at 2.02 ppm, Cr at 3.0 ppm, Cho at
3.2 ppm, Glx at 2.1 to 2.5 ppm and mI at 3.5 ppm.
The first spectrum was acquired from the right pre-
central gyrus and the peak ratios are printed on the
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Fig.2. Coronal T2-weighted fast spin-echo (FSE) images (5600
/90) shows frontal lobes atrophy (arrows) more prominent on the
Fig. 3. Axial T2-weighted fast spin-echo (FSE) images (8500/
2200/126) shows symmetrical high signal intensity of the cortico-
spinal tracts (within the posterior limbs of both internal capsu-
les) at the level of anterior commissure (arrows).
Fig. 4. Axial diffusion-weighted images (DWI) (3000/108) shows
hyperintense corticospinal tracts (within the posterior limbs of both
internal capsules) at the level of anterior commissure (arrows).
Fig. 5. Axial diffusion-weighted image (DWI) (3000/108) shows a
curvilinear hypointensity (arrows) in the region of the motor cor-
tex of the precentral gyri.
screen, as they appeared in (Figure 6): NAA/Cr = 1.20
(decreased for 10% compared to normal gray matter);
Cho/Cr = 0.87 (increased about 32%); Glx/Cr = 0.17 (de-
creased, 10%); mI/Cr 0.55 (normal). An additional spec-
trum was acquired from the right frontal white matter
and the area peak ratios were (Figure 7): NAA/Cr 0.94
(reduced for 33%); Cho/Cr = 0.95 (increased for 13%);
Glx/Cr = 0.3 (decreased 14%); mI/Cr = 0.68 (decreased
10%). The area peak ratios from the right corticospinal
tract at the level of cerebral peduncle (Figure 8) were:
NAA/Cr = 1.18 (decreased for 14%), Cho/Cr (normal),
Glx/Cr (decreased 16%) and mI/Cr = 0.68 (within the
normal range). The metabolite ratio of the right cortico-
spinal tract at the level of internal capsule was: NAA/Cr
= 1.2 (decreased for 14%); Cho/Cr = 0.9 (decreased for
12%); Glx/Cr = 0.29 (decreased for 10%); mI/Cr = 0.63
(normal).
Discussion
To our knowledge, this study is the first attempt to
demonstrate findings of MRI and MRS of the precentral
gyrus, frontal white matter and corticospinal tract at the
level of anterior commisure and cerebral peduncle in the
patient with ALS-FTD and to determine relationship
among results of current techniques.
Brain images were generally consistent with previous
findings in ALS23,24,25. Conventional MRI excluded brain-
stem lesion in the presence of bulbar signs and revealed
disproportionate frontotemporal atrophy, enlargement of
the central sulcus, hypointensity in the motor cortex
(thought to be due to iron deposition) and hyperintense
cortiscospinal tracts (within the posterior limbs of both
internal capsules) at the level of anterior commissure
and cerebral peduncle. However, absence of unequivocal
UMN signs has not correlated with noticeably MRI find-
ing that suggested UMN affection. In contrast to this
finding, clinical pattern of FTD reflected the topographic
pattern of frontal lobes atrophy visible on MR images.
Slightly reduced NAA/Cr ratio (10%) was detected in
the motor cortex location, in the corticospinal tract at the
level of cerebral peduncle and anterior commissure (14%)
and very much decreased in the frontal white matter
(33%). Because NAA is considered a neuronal marker,
our results of decreased NAA/Cr ratio in frontal white
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Fig. 6. Magnetic resonance spectroscopy (MRS) of the right pre-
central gyrus (motor cortex) region. Axial T2-weighted FSE (8500
/2200/126) was obtained. MRS demonstrates peaks of NAA at 2.02
ppm, Cr at 3.0 ppm, Cho at 3.2 ppm, glutamate and glutamine at
2.1 to 2.5 ppm and mI at 3.5 ppm. Spectra shows decreased NAA
/Cr (10%), Glx/Cr (10%), increased Cho/Cr ratio (32%) and normal
mI/Cr ratios. NAA – N-acetylaspartate, Cr – creatine, Cho – cho-
line, Glx – glutamate and glutamine, mI – myo-inositol.
Fig.7. MRS of the right frontal white matter region shows reduc-
tion in NAA/Cr (33%), Glx/Cr ratios (14%), increased Cho/Cr (13%)
ratio and normal mI/Cr ratio.
Fig. 8. MRS of the right corticospinal tract region at the level of ce-
rebral peduncle shows reduced NAA/Cr (14%), Glx/Cr ratio (16%),
increased Cho/Cr ratio (10%) and normal mI/Cr ratio.
matter suggested frontal lobes neuronal degeneration.
Because no significant reduction in NAA values has been
observed in the motor cortex, these results may be inter-
preted as evidence of non-significant UMN degeneration
and fully correspond with absent clinical signs of UMN
affection. Previous studies have shown higher NAA val-
ues in the white than in the grey matter in healthy
controls26. An additional MR spectroscopic abnormality
was excess of Cho/Cr ratio, more pronounced in the
precentral gyrus (32%) than in the frontal white matter
(13%) and corticospinal tracts (10%) at the levels of cere-
bral peduncle and anterior commissure. Raised Cho in
the precentral gyrus of the current patient differs from
the results of Gredal and colleagues27 who found no in-
crease in Cho level, but our results partially correspond
with 10% increase in Cho/Cr ratio reported by Block et
al17. Axonal degeneration, demyelination29 of subcortical
white matter may contribute in higher Cho of precentral
gyrus. We found normal level of the mI (glial marker).
Normal mI values have been found in all measured VOI.
These findings differ from the previous findings in ALS
or FTD alone. Block et al detected 16% increase in the
mI/Cr ratio in the precentral gyrus of ALS patients. Ra-
tio of mI/Cr was not sufficiently raised to bring these re-
sults into the range of FTD.
The patient presented in our study is an example of a
more difficult case because an additional metabolite ab-
normality was detected. An astrocyte marker (Glx) was
significantly reduced, corresponding with results from
previous studies. Perry and colleagues30 reported that
Glx is decreased up to 45%, selectively in the motor cor-
tex of ALS patients. In contrast to this, we found reduced
Glx/Cr ratio in the corticospinal tract at the level of in-
ternal capsule for 10%; in the corticospinal tract at the
level of cerebral peduncle 16%, in the frontal white matter
for 14%, and in precentral gyrus (motor cortex) for 10%.
Although cognitive impairment have already been
documented in ALS18,19 and cognitive functioning has
been explored in patients with ALS by using a multi-
modal approach including MRS 9, no studies examining
in vivo the use of MRS for the detection and quantifica-
tion of neurodegenerative changes in both ALS-FTD has
not been performed. Despite of lacking pathologic confir-
mation, clinical diagnosis of ALS and FTD was firmly es-
tablished using institutional criteria for ALS and inter-
national clinical criteria for FTD, including additional
investigations such as neuropsychology, electromyogra-
phy, electroencephalography and brain imaging (struc-
tural and functional). Neuropsychological investigations
showed significant impairment of frontal lobes in the ab-
sence of severe amnesia and aphasia. These findings
strongly support the diagnosis of FTD and fully corre-
spond with findings reported in the literature12,13,15,20,21.
Although neuropsychological and psychiatric examina-
tion is highly specific in determining the cognitive and
behavioral disturbances in FTD, these methods do not
provide explanation of mechanisms by which brain is af-
fected in ALS plus FTD.
Beacuse FTD arises when gradual personality change
are associated with frontotemporal abnormalities visible
on MRI26–29 extensive neuroimaging has been performed.
On MRI, there was great anterior atrophy of both frontal
lobes, more pronounced on the right side.
The MRS study resulted in spectra entirely consistent
with the spectral pattern of ALS patients7–9, but not in
FTD. Previous studies showed that spectra obtained
from precentral gyrus (motor cortex) are characterized
by lower NAA/Cr and Glx/Cr ratios, and increased Cho
/mIratio. In our case, the spectra showed reduced NAA
/Cho ratio, prominently in the frontal white matter, de-
creased Glx/Cr ratio in all VOI, but more pronounced in
the corticospinal tract at the level of cerebral peduncle,
increased Cho/Cr (32%) especially in the precentral gy-
rus, and normal level of myo-inositol (mI) in all VOI.
Therefore, reduced NAA/Cho ratios suggested significant
neuronal loss in the regions examined, decreased Glx/Cr
ratio indicated neuronal and astrocyte loss and increased
Cho/mI and Cho/Cr ratios suggested diffuse axonal in-
jury. Spectra obtained, deviated the most in NAA/Cr ratio
in the frontal white matter, Glx/cr in all measured voxels
and Cho/Cr ratio especially in precentral gyrus. In paral-
lel to these findings, there were no similar abnormalities
from striatum and hippocampus. Reduced glutamate
from motoric and somatosensoric cortex and normal
level from striatum and hipppocampus is finding consis-
tent to ALS, not to dementia disorder30. In the presence
of normal mI, only decreased NAA/Cr ratio brought this
case into range of dementia of non AD type, whereas the
FTD was more likely.
One of the drawbacks of this study is that neuro-
pathologic confirmation was lacking and a very small
sample (only one patient), limited detection of statisti-
cally significant changes between patients. Nevertheless,
the clinical diagnosis was firmly established using estab-
lished international clinical criteria.
Conclusion
Conventional, MRI and MR spectroscopy represent
powerful diagnostic techniques for assessing neurodege-
neration in ALS-FTD condition by monitoring the bio-
chemistry of the brain. Proton spectroscopy may repre-
sent more specific methods for detecting UMN or LMN
(lower motor neuron) degeneration in ALS than MR im-
aging, taking into account presence and severity of clini-
cal UMN and LMN signs. By comparing the MR spectra
of the present patient, we confirmed the findings of the
previous reports investigating exclusively ALS patients.
We provided new observations regarding MR spectro-
scopic metabolic changes in both ALS and FTD that was
fully consistent with MR spectroscopic pattern in ALS
alone. In addition to the previous studies, we found de-
creased Glx in precentral gyrus, as well as in the frontal
white matter and corticospinal tract. We presumed that
it may be demonstrated in a large sample, that ALS-FTD
patients can be separated from controls with a high sure-
ness using combined MRI and MR spectroscopic tech-
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niques. However, much additional work is needed to
identify relationship among the results of MR imaging
and MR spectroscopy taking into account severity of clin-
ical UMN and LMN signs. An alternative imaging tech-
niques, such as diffusion tensor imaging (DTI) and mag-
netic transfer ratio (MTR) may help to overcome the
drawbacks of the combined MRI and MRS results. To de-
tect statistically significant changes between ALS-FTD
patients and among ALS subgroups, a larger sample size
of patients need to be used. A more comprehensive model
in a diagnosing ALS-FTD condition is needed by involv-
ing combined MRI and MRS. Additional research using
MRI, fMRI and MRS is underway in our Centre to sup-
port antemortem diagnosis of ALS-FTD patients.
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MAGNETSKA REZONANCIJA I SPEKTROSKOPIJA MAGNETSKOM REZONANCIJOM U PACIJENTICE
S AMIOTROFI^NOM LATERALNOM SKLEROZOM I FRONTOTEMPORALNOM DEMENCIJOM
S A @ E T A K
Brojne su studije istra`ivale upotrebu magnetske rezonancije (MRI) i spektroskopije magnetskom rezonancijom(MRS)
u dijagnostici pojedina~nih neurodegenerativnih bolesti, kao {to su amiotrofi~na lateralna skleroza(ALS) ili frontotempo-
ralna demencija(FTD) pojedina~no, ali ne i u kombiniranim stanjima kao {to je amiotrofi~na lateralna skleroza udru`ena
s frontotemporalnom demencijom (ALS-FTD). Prema na{im spoznajama, ova studija je prvi poku{aj usporedbe struktur-
nih abnormalnosti motori~kog korteksa, bijele tvari ~eonog re`nja i kortikospionalnog trakta pomo}u konvencionalnog
MRI-a i metaboli~kih promjena istih struktura mozga pomo}u MRS u pacijentice kod koje je dijagnosticirana ALS s vjero-
jatnom degeneracijom gornjeg motori~kog neurona udru`ene s FTD. Kod pacijentice je u~injen MRI mozga i naknadno
MRS. Dobiveni su spektri iz podru~ja motori~kog korteksa, bijele tvari ~eonong re`nja i kortikospinalnog trakta, a potom
izra~unati omjeri N-acetil aspartata (NAA) i kreatinina (Cr); kolina (Cho) i Cr; myo-inositola (mI) i Cr te glutamata i
glutamine (Glx). Analizirane su MRI snimke prvenstveno na pro{ireni centralni sulkus, povi{en signal u podru~ju korti-
kospinalnog trakta i atrofiju ~eonih re`njeva. Spektar je pokazao sni`ene omjere NAA/Cr i Glx/Cr, dok je omjer Cho/Cr bio
povi{en. MRI je otkrio pro{iren centralni sulkus, povi{en signal u podru~ju koritkospinalnog trakta i atrofiju ~eonih
re`njeva. MRS u prikazane pacijentice korelira s rezultatima prethodnih studija ALS, ali ne i FTD. Na{i rezultati po-
dupiru koncept da ALS, FTD i ALS-FTD predstavljaju razli~ite manifestacije jedinstvenog patolo{kog kontinuuma.
